#	Pagina
attuale pagina	/open-h2020/projects/208165/index.html
-1	/open-h2020/per-topic/molemat/list/index.html

Opendata, web and dolomites

CG-100

A next generation medical device that enhances patient care and treatment following colorectal surgery

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CG-100 project word cloud

Explore the words cloud of the CG-100 project. It provides you a very rough idea of what is the project "CG-100" about.

company procedure dec care al hernia talks 50 subcontractors external moving quality prevent multiple patient colorectal content threatening anastomotic mark sepsis entrepreneurs israel bypass received trials time leads depression risky functions parastomal place cancer stage internal faecal stoma diseases pains reducing shown vast skin chronic surgeons founded life profound marketing patients single complications healing improves ulcers advisors proprietary companies cg 2014 ostomy eur intraluminal device ltd healthcare confidently solution active causing economic doctors bag comprising surgery anastomosis site employ 2010 full leakage stomas colonic diverting cologuard ce team infections clinical leaks bags contact waste employees medical silicon headquartered complication date

Project "CG-100" data sheet

The following table provides information about the project.

Coordinator	COLOSPAN LTD Organization address address: 21 ATIR YEDA STREET city: KFAR SABA postcode: 4464316 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Project website	http://www.cologuard.co.il
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2017
Duration (year-month-day)	from 2017-03-01 to 2017-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	COLOSPAN LTD COLOSPAN LTD Organization address address: 21 ATIR YEDA STREET city: KFAR SABA postcode: 4464316 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (KFAR SABA)	coordinator	50˙000.00

Map

Project objective

Cologuard Ltd is a clinical stage medical device company founded in Dec 2010. Cologuard's novel and proprietary technology for colorectal surgery was developed in order to prevent the profound clinical and economic pains associated with anastomotic leaks and diverting colonic stomas. Anastomotic leakage (AL) is a life threatening complication, which can occur following colorectal surgery for colorectal cancer or other diseases. In order to prevent AL, surgeons use a procedure called diverting stoma, which result in an ostomy bag for external bypass of waste. This solution leads to a low quality of life for patients, causing many clinical complications, including sepsis, parastomal hernia, ulcers, chronic depression and skin infections. In addition, this procedure has a high economic cost for the patient and the healthcare system. The Cologuard team have developed the CG-100, a single use intraluminal device composed of silicon, which functions as an internal bypass for colonic content, reducing contact between faecal content and the anastomosis site. The device allows healing to take place without the need for an external diverting stoma and ostomy bag. The CG-100 device improves patient care through the reduction of risky complications associated with ostomy bags, improving the healing process and providing a better quality of life. Healthcare costs will be greatly reduced by up to 50%. The company is composed of a strong team comprising top doctors and medical advisors as well as entrepreneurs with vast experience in the medical device sector. The company received CE mark for its lead product in 2014 and is confidently moving towards pre-marketing clinical trials in the EU. Cologuard has received over 4.2 M EUR funding to date. The company is headquartered in Israel and employ 5 full time employees and multiple subcontractors. The company is currently in talks with companies in the EU who have shown an active interest in the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CG-100" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CG-100" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination